Oventus Medical Ltd. announce the interim results of a clinical study being conducted in collaboration with NeuRA (Neuroscience Research Australia) on patients with Obstructive Sleep Apnoea (OSA) using Oventus' O2Vent oral applinces. Oventus' O2Vent oral appliance device with builtin proprietary airway technology shown to significantly reduce Obstructive Sleep Apnoea events (Apnoea-Hypopnoea Index (AHI)reduced median number of events per hour from 34.4 to 7.0 events/hour sleep, p=0.03 ­a reduction of 80%); O2Vent shown to be as effective for patients with and without high nasal resistance; Increased nasal resistance may be a reason for non-response when using other oral appliances; Further evidence of the benefit of O2Vent technology by passing multiple levels of obstruction; Abstract to be presented by leading NeuRA sleep and respiratory physiologist and Principal Investigator, Associate Professor Danny Eckert; The NeuRA study is funded by the Australian Federal government's $2.95 million CRC-P grant.